RTTR Ritter Pharmaceuticals Inc.

0.83
0  -0%
Previous Close 0.83
Open 0.8
Price To Book 41.5
Market Cap 7505134
Shares 9,042,330
Volume 111,984
Short Ratio
Av. Daily Volume 508,066

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due early 4Q 2019.
RP-G28
Lactose intolerance

Latest News

  1. Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
  2. Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
  3. Will Ritter Pharmaceuticals, Inc.'s (NASDAQ:RTTR) Earnings Grow Over The Next Few Years?
  4. Ritter Pharmaceuticals Reports Year End 2018 Financial Results and Provides Business Update
  5. Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
  6. Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals
  7. Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019
  8. What Type Of Shareholder Owns Ritter Pharmaceuticals, Inc.’s (NASDAQ:RTTR)?
  9. Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019
  10. Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
  11. Consolidated Research: 2018 Summary Expectations for E*TRADE Financial, Ballantyne Strong, Lincoln Educational Services, Electro-Sensors, Capital Southwest, and Ritter Pharmaceuticals — Fundamental Analysis, Key Performance Indications
  12. Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress
  13. Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
  14. Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants
  15. Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance